Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT05756569
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
- NCT05756569 ↗
- Recruiting
- Emory University
- Focused
We haven't built an HCP commentary report on NCT05756569 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05756569 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase II Single-Arm Study of Enfortumab Vedotin (EV) Plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Bladder Squamous Cell Carcinoma; Locally Advanced Bladder Carcinoma; Malignant Renal Pelvis Neoplasm; Malignant Ureter Neoplasm; Malignant Urethral Neoplasm; Metastatic Bladder Carcinoma; Stage III Bladder Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Unresectable Bladder Carcinoma; Urachal Adenocarcinoma; Bladder Adenocarcinoma
- Interventions
- Biospecimen Collection; Computed Tomography; Enfortumab Vedotin; Magnetic Resonance Imaging; Pembrolizumab; Questionnaire Administration
- Arms
- Treatment (enfortumab vedotin, pembrolizumab) · Experimental
- Enrollment
- 25 (estimated)
- Primary outcomes
- Overall response rate
- Sponsor
- Emory University with National Cancer Institute (NCI), Seagen Inc., Astellas Pharma Inc, Merck Sharp & Dohme LLC
- Start
- Sep 26, 2023
- Primary completion
- Dec 16, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05756569 · updated Jul 29, 2026